{"analyses":[{"ciLowerLimit":"-1.47","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.47","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.48","groupDescription":"Change at Week 1: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.3003","paramType":"Difference in LS mean","paramValue":"-0.50","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-2.03","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.35","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.59","groupDescription":"Change at Week 2: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1603","paramType":"Difference in LS mean","paramValue":"-0.84","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-2.13","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.53","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.66","groupDescription":"Change at Week 4: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.2298","paramType":"Difference in LS mean","paramValue":"-0.80","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-1.93","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.97","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.72","groupDescription":"Change at Week 6: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.5054","paramType":"Difference in LS mean","paramValue":"-0.48","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-2.10","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.01","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"-0.77","groupDescription":"Change at Week 8: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4793","paramType":"Difference in LS mean","paramValue":"-0.55","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-1.83","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.83","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.66","groupDescription":"Change at Week 12: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.4496","paramType":"Difference in LS mean","paramValue":"-0.50","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-2.77","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.36","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.77","groupDescription":"Change at Week 16: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1263","paramType":"Difference in least square LS mean","paramValue":"-1.21","statisticalMethod":"ANCOVA"},{"ciLowerLimit":"-2.54","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.44","dispersionType":"STANDARD_ERROR_OF_MEAN","dispersionValue":"0.73","groupDescription":"Change at Week 24: ANCOVA model for imputed datasets included treatment, region, and randomization stratification variables (concomitant anticancer treatment and tumor aggressiveness) as fixed effects, and baseline average pain intensity at the index bone metastasis cancer pain site and baseline opioid dose as covariates.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"0.1620","paramType":"Difference in LS mean","paramValue":"-1.05","statisticalMethod":"ANCOVA"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.42","value":"-0.64"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was 1.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was 0.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.35","value":"-1.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.54","value":"-0.96"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was 0.5","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was 1.5","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.47","value":"-1.81"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.59","value":"-1.42"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value were -1 and 0.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was 0.5","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.52","value":"-2.22"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 4"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.65","value":"-1.76"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value were -1 and -3.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was 0.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.56","value":"-2.24"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 6"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.70","value":"-1.79"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual values were -2 and -3.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual value was -2.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.62","value":"-2.34"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 8"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.59","value":"-1.64"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual values were -2 and -1.375.","groupId":"OG001","spread":"NA","value":"NA"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual values was -1.","groupId":"OG002","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.53","value":"-2.14"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 12"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.71","value":"-1.06"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual values were -2 and -1.375.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.60","value":"-2.27"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 16"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.68","value":"-0.87"},{"comment":"Data for this arm was not summarized per plan. Hence, not reported as LS mean and SE.\n\nIndividual values were -2.","groupId":"OG001","spread":"NA","value":"NA"},{"groupId":"OG003","spread":"0.59","value":"-1.92"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"title":"Change at Week 24"}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"32"}],"units":"Participants"}],"description":"Weekly average pain intensity in the non-index cancer pain site was assessed by participants on an 11 point pain intensity NRS ranging from 0 (no pain) to 10 (worst possible pain), where higher scores signified more severity of pain. Non-index cancer pan sites were the most painful cancer pain sites other than the index bone metastasis cancer pain site. The participants described their weekly pain at the painful site by choosing the appropriate number from 0 to 10 on IRT diaries. Baseline weekly average pain intensity was weekly average pain intensity NRS score recorded on any day during the baseline assessment period. Five days prior to dosing was considered as baseline assessment period. The Weeks 1, 2, 4, 6, 8, 12, 16 and 24 weekly average pain intensity value was the weekly average pain intensity NRS scores recorded on any day from the span of 7 days prior to specified week.","dispersionType":"Standard Error","groups":[{"description":"Participants received placebo matched to tanezumab SC once every 8 weeks for 24 weeks.","id":"OG000","title":"Placebo"},{"description":"Participants in this discontinued treatment arm, received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and completed their treatment before the amendment.","id":"OG001","title":"Tanezumab 10 mg"},{"description":"Participants in this treatment group had received tanezumab 10 mg SC once every 8 weeks before protocol amendment 3 and after the amendment they continued remaining treatment with tanezumab 20 mg SC once every 8 weeks.","id":"OG002","title":"Tanezumab 10/20 mg"},{"description":"Participants received tanezumab 20 mg SC once every 8 weeks for 24 weeks.","id":"OG003","title":"Tanezumab 20 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The mITT analysis set: participants randomized to tanezumab 20 mg or placebo SC, received at least 1dose of SC study medication. Multiple imputation method was applied. As planned summarized efficacy data for tanezumab 10 mg and 10/20 mg arms not reported; for these 2 arms individual values are reported. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure and ''number analyzed'' signifies participants evaluable at specified time points.","reportingStatus":"POSTED","timeFrame":"Baseline, Weeks 1, 2, 4, 6, 8, 12, 16 and 24","title":"Change From Baseline in the Weekly Average Pain Intensity NRS Score in Non-Index Cancer Pain Sites at Weeks 1, 2, 4, 6, 8, 12, 16 and 24","type":"SECONDARY","unitOfMeasure":"Units on a scale"}